Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $53.5152W HIGH $63.50
Volume
13.88 M
Value Traded
881.26 M
Short % Float
0.09%
+1.57%Week
+7.61%1 Month
+5.19%3 Month
+15.48%6 Month
+19.28%5 Year
+217.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.52 B
EPS (TTM)
-2.27
P/E Ratio
-
Ent. Value
16.13 B
Total Shares
181.51 M
Float Shares
180.36 M
Insiders
0.01%
Institutions
0.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CTLT Catalyst Timeline
Dated clinical, regulatory and corporate events for Catalent, Inc.
Past FDA Catalysts and PDUFA Decisions
How CTLT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$22M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Catalent, Inc. faces pipeline headwinds (25/100), with $131M risk-adjusted pipeline value, led by anle138b in Parkinson Disease (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| anle138b Small moleculeCompletedNCT04685265 | Parkinson Disease | Phase 1 | COMPLETED | 70 | Dec 22, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CTLT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ryan Michelle RDirector | Sell | -2,800 10,835 held | $59.70 | 11/11/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in CTLT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 2.1 % (5 %) | 36.07 M | 595.57 K |
CTLT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTLT ranks across every disease it competes in
Competitive Position is a premium feature
See how CTLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTLT News
About Catalent, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next CTLT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime